Cadrenal Therapeutics, Inc.

Aug 13, 2026

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

Cadrenal Therapeutics reported its Q2 2026 financial results and updates on its Cardiac Acute Critical Care Franchise. The company achieved regulatory guidance for CAD-1005's Phase 3 path and presented promising Phase 2 data at an international congress. Cadrenal is pursuing a structured partnering process to enhance its portfolio and address unmet needs in critical care cardiology.

Aug 3, 2026

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation

Cadrenal Therapeutics has consolidated its strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This move follows the discontinuation of a competitor's Phase 3 trial, highlighting the urgent need for novel treatments in this area. CAD-1005 has shown promising clinical data, positioning it as a first-in-class therapy in a lucrative market.

Jul 21, 2026

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

Cadrenal Therapeutics has initiated a partnering process for its cardiac acute critical care assets, including CAD-1005, frunexian, and tecarfarin. The company aims to secure strategic partnerships for these late-stage therapies following positive Phase 2 data presented at the ISTH 2026 Congress. This strategic alignment is designed to maximize asset value and address unmet needs in critical care cardiology.

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Cadrenal Therapeutics presented late-breaking Phase 2 data for CAD-1005 at the ISTH 2026 Congress, showing over a 25% reduction in thrombotic events in patients with Heparin-Induced Thrombocytopenia (HIT). This trial is notable as the first randomized, blinded, placebo-controlled study in this area. The results support the advancement of CAD-1005 towards Phase 3 trials, addressing a significant medical need.

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cadrenal Therapeutics has announced a private placement of up to $8.8 million, with $3 million upfront and potential additional proceeds from warrants. The funds are expected to extend the company's cash runway into 2027, allowing for the advancement of therapies for Kawasaki Disease and other conditions. The offering is set to close on July 1, 2026, pending customary conditions.

Jun 24, 2026

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

Cadrenal Therapeutics announced that its Phase 2 study of CAD-1005 has been selected for a late-breaking oral presentation at the ISTH 2026 Congress. This trial is the first randomized, blinded, placebo-controlled study for Heparin-Induced Thrombocytopenia (HIT), a serious blood-clotting disorder. The presentation will highlight the clinical potential of CAD-1005, a novel 12-lipoxygenase inhibitor, which could transform treatment for HIT patients.

Jun 18, 2026

▲ +12.9%on this newsshared move

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Cadrenal Therapeutics is preparing to file for a Rare Pediatric Disease Designation for tecarfarin, aimed at treating Kawasaki disease in children. This designation could lead to a Priority Review Voucher, enhancing the drug's market potential. The company will showcase its initiatives at the upcoming BIO International Convention, highlighting its Phase 3-ready pipeline.

Jun 15, 2026

▼ -10%on this newsshared move

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Cadrenal Therapeutics announced plans to initiate a Phase 2a clinical trial for CAD-1005, targeting Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This indication expands the drug's potential market, estimated at $1 billion annually, as there are currently no FDA-approved therapies for CSA-AKI. The trial aims to generate safety and efficacy data while leveraging existing research on CAD-1005's use in heparin-induced thrombocytopenia (HIT). Discussions about this strategy will take place at the upcoming BIO 2026 conference.

Jun 3, 2026

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Cadrenal Therapeutics is set to showcase its Phase 3-ready CAD-1005 and 12-LOX platform at the BIO International Convention 2026. CAD-1005 targets Heparin-Induced Thrombocytopenia (HIT) and has received FDA designations for its potential to address unmet medical needs. The company aims to explore broader applications for its 12-LOX inhibitor platform, which may impact various inflammatory diseases. Tecarfarin, another late-stage product, is designed for patients with complex anticoagulation needs.

May 19, 2026

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The company will host a webcast presentation and one-on-one meetings with investors. Cadrenal is focused on developing therapies for immune and thrombotic conditions, including its lead program CAD-1005, which targets heparin-induced thrombocytopenia.

May 7, 2026

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Cadrenal Therapeutics reported its Q1 2026 financial results and provided an update on its CAD-1005 program following an End-of-Phase 2 meeting with the FDA. The company plans to advance to a pivotal Phase 3 trial for CAD-1005, aimed at treating heparin-induced thrombocytopenia (HIT). The trial will evaluate CAD-1005's efficacy in approximately 120 patients and is intended to support a New Drug Application by 2029. Positive Phase 2 data indicated a significant reduction in thrombotic events, reinforcing the drug's potential.

May 7, 2026

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA Official FDA meeting minutes and Phase 2 data provide guida

Cadrenal Therapeutics reported its financial results for the first quarter of 2026 and updated on the development of CAD-1005, a treatment for heparin-induced thrombocytopenia (HIT). The company has received FDA guidance following their End-of-Phase 2 meeting, which outlines the path for a pivotal Phase 3 trial. Cadrenal plans to move directly to a randomized, placebo-controlled study, building confidence that CAD-1005 could become the first new therapy for HIT in over 20 years. Financially, the company experienced reduced operating expenses but reported a net loss of $2.5 million.

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Cadrenal Therapeutics announced a successful End-of-Phase 2 meeting with the FDA, receiving guidance for a pivotal Phase 3 trial of CAD-1005 in treating heparin-induced thrombocytopenia (HIT). The Phase 2 results indicated a significant reduction in thrombotic events when CAD-1005 was added to standard therapy. The upcoming Phase 3 study aims to evaluate CAD-1005's efficacy in a randomized, placebo-controlled setting.

Apr 30, 2026

▲ +19.3%on this newsshared move

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) FDA provided critical guidance for the advancement of CAD-1

Cadrenal Therapeutics has announced a significant regulatory milestone following its successful End-of-Phase 2 meeting with the FDA regarding CAD-1005, aimed at treating heparin-induced thrombocytopenia (HIT). The FDA provided essential guidance for Cadrenal's plan to move forward with a pivotal Phase 3 registration study, which will evaluate CAD-1005 in around 120 patients globally. The Phase 3 study intends to support a new drug application by 2029, marking CAD-1005 as a potential groundbreaking therapy for HIT, which has not seen new treatment options in decades.

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

Cadrenal Therapeutics reported its fourth quarter 2025 financial results and provided an update on its CAD-1005 program for heparin-induced thrombocytopenia (HIT). The company completed its End-of-Phase 2 meeting with the FDA, clarifying the path for a Phase 3 trial. Encouraging Phase 2 results showed a significant reduction in thrombotic events, reinforcing CAD-1005's potential as a treatment option.

Mar 31, 2026

▲ +20.5%on this newsshared move

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting Encouraging Phase 2 HIT data and recent FDA feedback support

Cadrenal Therapeutics has reported its fourth quarter 2025 financial results along with an update on its CAD-1005 program for heparin-induced thrombocytopenia (HIT). The company revealed that encouraging Phase 2 data supports continued development of CAD-1005 as a priority, following a successful End-of-Phase 2 meeting with the FDA. Although the company is experiencing financial losses, the progress in clinical development and FDA collaboration signifies potential advancements in treatment for HIT.

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

Cadrenal Therapeutics has announced promising research highlighting the potential of its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, in reducing inflammation associated with obesity and Type 2 diabetes. The findings suggest that 12-LOX inhibition may improve glucose homeostasis and peripheral inflammation. Additionally, CAD-1005 has shown significant benefits in preclinical models and has been successful in a Phase 2 trial for treating Heparin-Induced Thrombocytopenia (HIT). The company aims to explore further applications of 12-LOX inhibition in various inflammatory conditions.

Mar 2, 2026

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

Cadrenal Therapeutics announced promising results from a Phase 2 study of CAD-1005, a selective 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT). The company plans to hold an End-of-Phase 2 meeting with the FDA soon. Additionally, the acquisition of a 12-LOX inhibitor portfolio opens avenues for treating various inflammatory and thrombotic conditions, potentially addressing significant market needs.

Feb 24, 2026

▲ +16.1%on this news· ran to +29% by day 1

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Cadrenal Therapeutics announced positive Phase 2 trial results for CAD-1005 in patients with heparin-induced thrombocytopenia (HIT), showing a greater than 25% reduction in thrombotic events compared to placebo. Although the primary endpoint of platelet count recovery was not met, the secondary endpoint results were encouraging. An End-of-Phase 2 meeting with the FDA is scheduled to discuss the path forward for Phase 3 trials.

Jan 12, 2026

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Cadrenal Therapeutics presented at the J.P. Morgan Healthcare Conference, highlighting the unmet medical need in heparin-induced thrombocytopenia (HIT) and the potential of VLX-1005, a selective 12-LOX inhibitor. Emerging Phase 2 trial data suggest VLX-1005 may effectively reduce thrombotic complications associated with HIT. The company is engaging with the FDA for a pivotal Phase 3 study.

Dec 30, 2025

Cadrenal’s Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

Cadrenal Therapeutics is positioning itself as a leader in anticoagulation management by addressing critical gaps in treatment for high-risk patients. Its pipeline includes tecarfarin, a Phase 3-ready therapy for patients with end-stage kidney disease, and VLX-1005, a Phase 2 candidate for heparin-induced thrombocytopenia. The recent acquisition of Factor XIa inhibitors further strengthens its acute care offerings, making Cadrenal a significant player in the healthcare system.

Dec 29, 2025

▼ -6.7%on this newsshared move

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

Cadrenal Therapeutics is innovating in the anticoagulation space by targeting high-risk patients often neglected by traditional therapies. Their lead asset, tecarfarin, is designed for patients with unstable renal function and complex cardiac issues. Recent acquisitions, including a Factor XIa inhibitor and VLX-1005 for heparin-induced thrombocytopenia, enhance their portfolio, positioning the company as a leader in addressing critical gaps in anticoagulation management.

Dec 18, 2025

▼ -7.2%on this news

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Cadrenal Therapeutics, Inc. will hold partnering and investor meetings during the J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. CEO Quang X. Pham emphasized the importance of these meetings for discussing strategies and recent acquisitions aimed at improving anticoagulation therapies. The company is targeting the $40 billion anticoagulation market with innovative solutions.

Dec 11, 2025

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Cadrenal Therapeutics has acquired VLX-1005, a first-in-class Phase 2 12-LOX inhibitor, from Veralox Therapeutics. This acquisition enhances Cadrenal's pipeline, targeting heparin-induced thrombocytopenia (HIT), a serious condition affecting many patients. VLX-1005 has shown encouraging results in reducing thromboembolic events in clinical studies and has received regulatory designations to expedite its development.

Dec 11, 2025

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) Novel first-in-class therapeutic targeting a key immune si

Cadrenal Therapeutics has acquired VLX-1005, a first-in-class 12-LOX inhibitor aimed at treating Heparin-Induced Thrombocytopenia (HIT). This acquisition is expected to bolster Cadrenal's product pipeline and target a significant unmet need in anticoagulation therapy, aligning with their commitment to developing transformative therapeutics. VLX-1005 has already shown promising results in prior studies, suggesting it may improve patient outcomes and mitigate thromboembolic risks associated with HIT.

Dec 1, 2025

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

Cadrenal Therapeutics has appointed Dr. Lee Golden to its Board of Directors, effective immediately. Dr. Golden, who has extensive experience in clinical development within cardiovascular medicine, will serve as an independent director. His addition is seen as a strategic move to advance the company’s mission to develop better anticoagulant therapies, especially with products like tecarfarin. The CEO expressed optimism about Dr. Golden's track record in guiding therapies through clinical pathways as beneficial for the company’s objectives.

Nov 19, 2025

▼ -5.6%on this news· ran to -16% by day 3

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award

Quang X. Pham, CEO of Cadrenal Therapeutics, has been awarded the Executive of the Year by BioFlorida at the Florida Innovation Conference. This recognition highlights his leadership in advancing the company's mission to develop innovative anticoagulant therapies. Cadrenal is focused on addressing critical gaps in anticoagulation treatment with its two clinical-stage products.

Nov 10, 2025

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics announced its financial results for the third quarter of 2025, reporting a net loss of $2.7 million. The company aims to advance tecarfarin and frunexian to address gaps in current anticoagulation treatments. CEO Quang X. Pham emphasized the strategic partnerships being formed to enhance development strategies. Although research and administrative expenses saw an increase, Cadrenal continues to target underserved patient populations with its novel therapies.

Sep 29, 2025

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The event will feature a webcast presentation and one-on-one meetings with investors. The company is focused on developing tecarfarin, a novel anticoagulant aimed at addressing gaps in current therapies.

Sep 15, 2025

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors

Cadrenal Therapeutics has acquired eXIthera Pharmaceuticals' portfolio of Factor XIa inhibitors, significantly enhancing its pipeline in anticoagulation therapy. This acquisition includes the Phase 2-ready intravenous agent frunexian and the oral candidate EP-7327, targeting critical gaps in current treatments. Cadrenal aims to address the needs of patients with cardiovascular thrombotic risks and plans to expand its capabilities in this area.

Sep 15, 2025

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors Acquisition significantly enhances the Company's pipeline by adding novel

Cadrenal Therapeutics has announced the acquisition of eXIthera Pharmaceuticals' portfolio of Factor XIa inhibitors, including the lead asset frunexian. This acquisition significantly expands Cadrenal's pipeline and targets an underserved segment of the $38 billion anticoagulation market. The newly acquired assets are designed to address critical gaps in current therapies, particularly for patients at high risk of thrombotic conditions. Cadrenal aims to leverage these innovative therapies to strengthen its position in the anticoagulation sector.

Aug 11, 2025

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics reported its Q2 2025 financial results and outlined plans for a clinical trial of tecarfarin in patients with end-stage kidney disease transitioning to dialysis. The company emphasized the urgent need for effective anticoagulants in this population. Despite a net loss of $3.7 million, Cadrenal's advancements in operational execution and strategic collaborations position it favorably for future growth.

Aug 11, 2025

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Announces strategic clinical trial plans for tecarfarin in patients with End-Stage Kidney Disease (ESKD) transitioning to

Cadrenal Therapeutics reported its financial results for the second quarter of 2025 while detailing plans to initiate a clinical trial for tecarfarin in patients with end-stage kidney disease (ESKD) transitioning to dialysis. The company aims to address critical treatment gaps in this patient population, which is at high risk for thrombotic events. Tecarfarin's orphan drug and fast-track designations highlight its potential. Cadrenal also continues to seek business development collaborations to enhance its clinical pipeline.

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Cadrenal Therapeutics has announced plans to initiate a clinical trial for tecarfarin in patients with end-stage kidney disease (ESKD) transitioning to dialysis. The trial aims to address significant risks associated with this patient population, particularly regarding thrombotic cardiovascular events. Tecarfarin's unique metabolism may offer a safer anticoagulation option for these patients, especially those with atrial fibrillation.

Aug 5, 2025

▲ +23.7%on this newsshared move

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis Advances knowledge about the use of tecarfar

Cadrenal Therapeutics, Inc. has announced plans to initiate a clinical trial for tecarfarin, aimed at patients with end-stage kidney disease (ESKD) transitioning to dialysis. The trial intends to address a critical treatment gap, particularly in high-risk groups for thrombotic cardiovascular events. Enrollment is set to begin later this year, focusing on both ESKD patients with and without atrial fibrillation (AFib). Tecarfarin has been granted orphan drug and fast-track designations, emphasizing its potential impact on patient care in this underserved population.

Jun 12, 2025

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Cadrenal Therapeutics has announced new findings on the burdens faced by LVAD patients requiring chronic anticoagulation. The research highlights the high costs associated with bleeding events and introduces tecarfarin as a potential alternative to warfarin. Tecarfarin aims to provide consistent anticoagulation control with fewer complications, addressing significant unmet needs in this patient population.

Jun 4, 2025

▲ +13.1%on this news

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Cadrenal Therapeutics, Inc. will attend the BIO International Convention 2025 in Boston, where its executive team will engage with investors and potential partners. The focus will be on updates regarding the clinical development of their lead asset, tecarfarin, a novel anticoagulant aimed at improving treatment for cardiovascular disease. The convention is a major event in the biotechnology industry, attracting over 20,000 leaders.

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

Cadrenal Therapeutics has announced significant progress in the manufacturing of tecarfarin, a novel oral anticoagulant aimed at patients with cardiovascular disease. The company has completed the technical transfer and is currently manufacturing the drug product in compliance with cGMP. This advancement supports their clinical development strategy and highlights tecarfarin's potential benefits for patients requiring chronic anticoagulation.

May 8, 2025

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics reported its Q1 2025 financial results, highlighting leadership changes and strategic advancements in the development of tecarfarin. The company appointed Dr. James Ferguson as Chief Medical Officer and secured a collaboration agreement with Abbott to support its pivotal trial. Additionally, guidance from the FDA is expected to enhance the design of the upcoming Phase 3 trial for tecarfarin.

May 8, 2025

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update Leadership appointment strengthens strategic and development capabilities. FDA Type D Meeting provides additional guidance

Cadrenal Therapeutics reported its first-quarter financial results for 2025, highlighting a new leadership appointment and recent advancements in the clinical development of tecarfarin. The company received guidance from the FDA regarding a pivotal trial for tecarfarin, which is intended for patients with left ventricular assist devices. Additionally, a collaboration agreement with Abbott was announced to support the trial, underlining the market's demand for new anticoagulation therapies. Despite an increase in expenses and reported losses, the company's strategic direction remains focused on addressing unmet needs in cardiovascular treatment.

Apr 17, 2025

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Cadrenal Therapeutics, Inc. will present at the Centri Capital Conference on April 22, 2025. CEO Quang X. Pham will discuss the development of tecarfarin, their lead oral anticoagulant, which aims to address unmet needs in anticoagulation therapy. The conference will connect executives from various healthcare sectors with capital market attendees.

Apr 3, 2025

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Cadrenal Therapeutics, Inc. is participating in several major conferences in Q2 2025 to promote its oral anticoagulant, tecarfarin. Key representatives will engage with experts at the National Conference on Anticoagulation Therapy and the CMO Summit 360°. The company aims to enhance its pipeline and business development initiatives at the BIO International Convention in June.

Mar 13, 2025

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Cadrenal Therapeutics reported its full-year results for 2024, highlighting significant advancements in the clinical development of tecarfarin, an oral vitamin K antagonist. The company secured a collaboration with Abbott to support its Phase 3 TECH-LVAD trial and received guidance from the FDA for trial design. Leadership changes aim to enhance development capabilities, while the company raised $9.8 million to support its initiatives.

Mar 13, 2025

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in suppo

Cadrenal Therapeutics reported on March 13, 2025, its full year 2024 financial results and highlighted key steps taken toward advancing its drug tecarfarin into Phase 3 clinical development. Notable achievements include a collaboration agreement with Abbott to support the TECH-LVAD trial, as well as guidance received from the FDA regarding clinical trial design. The company raised approximately $9.8 million through various financing channels, while also incurring a net loss for the year. Cadrenal's strategic direction emphasizes addressing unmet needs in anticoagulation therapy.

Mar 4, 2025

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Cadrenal Therapeutics has announced a collaboration with Abbott to support the pivotal TECH-LVAD trial, which will evaluate the efficacy and safety of tecarfarin in patients with HeartMate 3 LVADs. Abbott will assist with trial design, site identification, and share insights from previous trials. This partnership aims to enhance patient outcomes through improved anticoagulation quality.

Mar 4, 2025

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3 LVAD Strengthens the Potential for Improved Patient Outcomes through Improvements

Cadrenal Therapeutics has entered into a collaboration agreement with Abbott to support its pivotal TECH-LVAD trial for tecarfarin, a new oral vitamin K antagonist aimed at patients with HeartMate 3 LVADs. The partnership will provide crucial expertise and resources, facilitating the trial's design and execution. Abbott will share insights from previous HeartMate 3 trials, aimed at assessing tecarfarin's efficacy and safety. This collaboration is expected to enhance patient enrollment and support Cadrenal's goal of innovating in anticoagulation therapy for advanced heart failure patients.

Feb 6, 2025

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics has appointed Dr. James J. Ferguson as its new Chief Medical Officer to lead the late-stage clinical development of tecarfarin, a new Vitamin K antagonist. Dr. Ferguson brings over 25 years of cardiovascular expertise, aiming to enhance the company's pipeline and address unmet needs in anticoagulation therapy. The pivotal Phase 3 trial for tecarfarin is planned for 2025.

Feb 6, 2025

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong suppor

Cadrenal Therapeutics has appointed Dr. James J. Ferguson as the new Chief Medical Officer to lead the late-stage clinical development of tecarfarin, a new vitamin K antagonist. Dr. Ferguson has over 25 years of experience in the cardiovascular field and replaces Douglas W. Losordo. The appointment is part of Cadrenal's strategy to advance tecarfarin, which has received Orphan Drug designation and aims to improve outcomes for patients with cardiovascular conditions requiring anticoagulation therapy. The company plans to initiate pivotal trials in 2025.

Feb 5, 2025

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Cadrenal Therapeutics, Inc. will present at the 2025 BIO CEO & Investor Conference, focusing on their lead product, tecarfarin, a new Vitamin K antagonist aimed at improving anticoagulation therapy for patients with implanted cardiac devices. CEO Quang X. Pham will provide updates on the company's progress and plans for a pivotal Phase 3 trial in 2025. Tecarfarin has received Orphan Drug designation for specific patient populations, highlighting its potential in addressing unmet medical needs.

Jan 9, 2025

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cadrenal Therapeutics, Inc. will participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025. CEO Quang X. Pham will engage in a webcasted fireside chat discussing the company's novel anticoagulant, tecarfarin, which is in advanced clinical development. Tecarfarin aims to provide a safer alternative for patients requiring chronic anticoagulation. The drug has received multiple designations from the FDA, highlighting its potential in treating specific patient populations.

Dec 31, 2024

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Cadrenal Therapeutics provided a year-end update emphasizing its 2024 milestones and plans for tecarfarin, an investigational anticoagulant. The company aims to initiate a pivotal Phase 3 trial for tecarfarin in LVAD patients in 2025. Additionally, Cadrenal has engaged with the FDA and raised significant funding to support its clinical development efforts.

Dec 18, 2024

▲ +13.2%on this news· ran to +27% by day 1

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Cadrenal Therapeutics is preparing for the 43rd Annual J.P. Morgan Healthcare Conference Week, scheduled for January 13-16, 2025. The company will present its Phase 3 clinical development and regulatory plan for tecarfarin, a novel anticoagulant. CEO Quang X. Pham will participate in significant discussions and investor meetings during this event, highlighting the drug's potential benefits for patients with specific cardiovascular conditions.

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Cadrenal Therapeutics has been awarded the title of 'Anticoagulation Therapy Company of the Year' by Pharma Tech Outlook for its innovative development of tecarfarin, a new anticoagulant. This recognition highlights the company's commitment to addressing the needs of patients with implanted cardiac devices and rare cardiovascular conditions. Tecarfarin is designed to improve patient outcomes by minimizing drug interactions and variability in dosing compared to traditional therapies like warfarin.

Nov 12, 2024

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Cadrenal Therapeutics presented at the EACTS Mechanical Circulatory Support Summit, showcasing data on tecarfarin, a new anticoagulant. The presentation emphasized tecarfarin's potential to improve therapeutic range and reduce bleeding in patients with the Abbott HeartMate3 LVAD. The company is advancing its clinical trial protocol with the FDA to evaluate tecarfarin's effectiveness compared to warfarin.

Nov 7, 2024

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Cadrenal Therapeutics provided a corporate update highlighting key developments for tecarfarin, a new anticoagulant. The company met with the FDA to discuss its Phase 3 trial protocol and advanced collaboration with Abbott for pivotal trials. Recent financing efforts raised nearly $10 million, enhancing Cadrenal's cash reserves as it prepares for clinical trials in 2025.

Nov 7, 2024

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER

Cadrenal Therapeutics has provided an update on its progress for the third quarter of 2024, highlighting significant milestones in the development of tecarfarin, an innovative anticoagulant. The company successfully raised nearly $10 million, which will support its operational and clinical development efforts. Tecarfarin is positioned as a safer alternative for patients requiring anticoagulation, particularly those with implanted cardiac devices or rare cardiovascular conditions. The company is planning pivotal clinical trials to establish tecarfarin's superiority over warfarin, with positive expectations for its market introduction in the near future.

Nov 1, 2024

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Cadrenal Therapeutics has announced the exercise of warrants for approximately $4.7 million in gross proceeds to advance its clinical development. The company is set to issue new unregistered Series A-1 and A-2 warrants with an exercise price of $16.50 per share. The raised funds will primarily be allocated towards a pivotal Phase 3 trial and pursuing partnerships. The offerings are expected to finalize by November 4, 2024, pending standard closing conditions.

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Cadrenal Therapeutics announced the successful raising of $5.1 million through its at-the-market facility by selling 391,243 shares of common stock at an average price of $13.15. The company aims to utilize the funds to enhance its cash reserves and to continue the development of tecarfarin, a novel anticoagulant, as it prepares for its pivotal Phase 3 trial. With this financing, Cadrenal has reported an increased cash balance of about $7.4 million, positioning it well for future clinical endeavors in treating patients with certain cardiovascular conditions.

Oct 23, 2024

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Cadrenal Therapeutics has announced its membership in the Corporate Council of the Anticoagulation Forum, reinforcing its commitment to improving anticoagulation therapy. The partnership will focus on addressing clinical needs, sharing research, and promoting educational initiatives for healthcare professionals. Tecarfarin, Cadrenal's new vitamin K antagonist, aims to enhance safety and efficacy in anticoagulation care.

Cadrenal Therapeutics, Inc. NASDAQ: CVKD September 2024 2 Caution Concerning Forward - looking Statements This document contains forward - looking statements . In addition, from time to time, we or our representatives ma

Cadrenal Therapeutics, Inc. is developing tecarfarin, a Phase 3-ready anticoagulant aimed at addressing the limitations of warfarin. The drug is designed to be safer and more effective, especially for patients with conditions such as left ventricular assist devices and end-stage kidney disease. Tecarfarin has received Orphan Drug Designations from the FDA, indicating it may fulfill unmet medical needs. With extensive safety data supporting its use, Cadrenal aims to expedite its path to market through strategic partnerships and collaborations.

Sep 23, 2024

▼ -5.6%on this news· ran to +35% by day 3shared move

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. The company will present a webcast and hold one-on-one meetings with investors. Cadrenal is focused on developing tecarfarin, a new vitamin K antagonist aimed at providing safer anticoagulation options for patients with specific cardiovascular conditions.

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Cadrenal Therapeutics is set to engage with the FDA in early September for a Type-B meeting regarding its clinical trial for tecarfarin in patients with Left Ventricular Assist Devices (LVADs). This meeting is pivotal as the company prepares for its upcoming trial. Tecarfarin aims to address the challenges faced by LVAD patients in anticoagulation therapy, particularly the limitations of current treatments like warfarin.

Aug 20, 2024

▲ +19.1%on this newsshared move

Published Findings Highlight Tecarfarin’s Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Cadrenal Therapeutics highlighted a recent study published in the Journal of Cardiac Failure, emphasizing the potential of tecarfarin as a next-generation anticoagulant for LVAD patients. The study suggests that tecarfarin may provide more stable anticoagulation compared to warfarin, which is associated with gastrointestinal bleeding. The findings indicate a critical need for improved anticoagulation therapies in this patient population.

Aug 14, 2024

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Cadrenal Therapeutics, Inc. will present at several upcoming investor conferences, including the Sidoti Micro-cap Virtual Conference and the Summer 2024 Investor Summit. The presentations will feature updates on their lead candidate, tecarfarin, which is designed to prevent blood clots in patients with specific cardiovascular conditions. The company has received multiple FDA designations for tecarfarin, indicating its potential significance in anticoagulation therapy.

Aug 7, 2024

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Cadrenal Therapeutics has provided a corporate update on its progress related to tecarfarin, an oral anticoagulant targeting patients with implanted cardiac devices. The company has advanced plans for a pivotal trial intended to evaluate tecarfarin's efficacy, aided by its recent orphan drug designation. Collaborations with Abbott aim to accelerate the development of tecarfarin for LVAD patients. Despite positive advances, the company acknowledges potential risks tied to trial outcomes and regulatory approvals.

Aug 6, 2024

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

Cadrenal Therapeutics has partnered with Abbott to collaborate on a pivotal study of tecarfarin, an innovative anticoagulant aimed at preventing thromboembolic events in patients with recently implanted left ventricular assist devices (LVADs). The FDA has granted tecarfarin Orphan Drug Designation for its potential to improve patient outcomes in this population. Previous research supports the efficacy of tecarfarin in enhancing anticoagulation quality, particularly for those on multiple medications or with renal impairments. This initiative is considered significant for the thousands of individuals relying on such devices for their heart health.

Jul 17, 2024

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Cadrenal Therapeutics, Inc. (CVKD) will present at the Emerging Growth Conference on July 18, 2024. The company is focused on tecarfarin, a new-generation anticoagulant aimed at preventing serious cardiovascular events. The presentation will be accessible via webcast, and management will hold one-on-one investor meetings following the conference.

Jun 11, 2024

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Cadrenal Therapeutics, Inc. will present at the Emerging Growth Conference on June 12, 2024. The presentation will focus on tecarfarin, a new-generation oral anticoagulant aimed at preventing serious cardiovascular events. Following the presentation, management will hold one-on-one investor meetings to discuss the company's developments further.

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

Cadrenal Therapeutics presented new trial data at the ISHLT conference, emphasizing the importance of anticoagulation quality in LVAD patients. The ARIES-HM3 trial revealed that improved time in therapeutic range (TTR) correlates with better patient outcomes. Tecarfarin, a novel anticoagulant, has received Orphan Drug Designation from the FDA and may address the deficiencies of warfarin in this patient population.

May 23, 2024

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company will present a webcast and hold one-on-one meetings with investors. Tecarfarin, their late-stage anticoagulant, targets patients with rare cardiovascular conditions and has received FDA designations for its development.

May 9, 2024

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

Cadrenal Therapeutics provided a corporate update highlighting key developments for tecarfarin, a novel anticoagulant. The company received FDA Orphan Drug Designation for tecarfarin aimed at preventing thromboembolism in patients with mechanical circulatory support devices. Additionally, they appointed a new COO and engaged CDMOs for clinical trial materials. The company emphasizes the urgent need for improved anticoagulation therapies.

Apr 11, 2024

▲ +6.3%on this news

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Cadrenal Therapeutics, Inc. will present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024. The presentation will include a Q&A session, allowing audience interaction. The company is focused on its late-stage anticoagulant, tecarfarin, which targets rare cardiovascular conditions and has received FDA designations.

Apr 9, 2024

▼ -19.9%on this newsshared move

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts FDA desi

Cadrenal Therapeutics has received Orphan Drug Designation from the FDA for its anticoagulant drug, tecarfarin, aimed at preventing thromboembolism and thrombosis in patients with mechanical circulatory support devices. This designation underscores the urgent need for effective anticoagulation treatments in this patient population, where current alternatives are inadequate. The ODD status potentially allows the company to benefit from market exclusivity and certain development incentives. Tecarfarin represents a significant advancement in addressing the unique anticoagulation needs of patients with ventricular assist devices.

Mar 11, 2024

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Cadrenal Therapeutics has provided a corporate update highlighting its progress with tecarfarin, an innovative anticoagulant designed for patients with rare cardiovascular conditions. The company reported increased recognition of the unmet needs in the market and achieved orphan drug designation, granting seven years of market exclusivity. Cadrenal has also strengthened its intellectual property and expanded manufacturing capabilities as it prepares for a pivotal trial. This update comes alongside their filed Annual Report for 2023, suggesting increased optimism for the company's future prospects.

Feb 26, 2024

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Cadrenal Therapeutics, Inc. will participate in the Technology and Heart Failure Therapeutics Conference (THT 2024) from March 4-6, 2024, in Boston. The company aims to discuss its anticoagulant tecarfarin, which targets unmet needs in patients requiring chronic anticoagulation therapy. Tecarfarin has received FDA designations for specific patient populations and has been well-tolerated in clinical trials.

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Cadrenal Therapeutics has appointed Jeff Cole as its new Chief Operating Officer, a strategic move ahead of the Phase 3 trial of their anticoagulant drug, tecarfarin. Cole brings over 25 years of experience in pharmaceutical operations, which the company hopes will support its manufacturing, commercialization, and development efforts. Tecarfarin aims to address significant unmet needs in anticoagulation therapy for patients with conditions such as end-stage kidney disease and atrial fibrillation. Prior to joining Cadrenal, Cole held senior roles at companies like Espero BioPharma and Valeant Pharmaceuticals.

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

Cadrenal Therapeutics has highlighted a peer-reviewed article that underscores the necessity for new anticoagulation therapies, particularly for patients with specific medical conditions where direct oral anticoagulants (DOACs) may not be effective. The article discusses the limitations of current treatments, emphasizing the potential role of tecarfarin, a novel Vitamin K Antagonist, in addressing these unmet needs. Cadrenal's tecarfarin is in late-stage development and has received orphan drug and fast track designations from the FDA.

Jan 24, 2024

▲ +19.3%on this news· ran to +55% by day 3

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Cadrenal Therapeutics, Inc. will participate in a fireside chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024. Douglas Losordo, M.D., the Chief Medical Officer, will lead the discussion, which can be accessed via webcast. The company will also hold one-on-one meetings with investors during the event.

Jan 4, 2024

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Cadrenal Therapeutics, Inc. will present its late-stage anticoagulant tecarfarin at the Biotech Showcase 2024, coinciding with the J.P. Morgan Annual Healthcare Conference. CEO Quang Pham will discuss the drug's potential benefits for patients with conditions like End-Stage Kidney Disease and Atrial Fibrillation. The company is also participating in one-on-one meetings during the event.

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

Noble Capital Markets has started coverage on Cadrenal Therapeutics, assigning an 'Outperform' rating and setting a price target of US$4.00 per share. The company is focused on developing tecarfarin, a novel anticoagulant aimed at preventing serious cardiovascular events in patients with orphan diseases. Tecarfarin has shown promise in clinical trials, indicating its potential in the market.

Dec 12, 2023

Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin’s Late-Stage Development and Commercialization

Cadrenal Therapeutics has partnered with The Sage Group to advance the late-stage development and commercialization of tecarfarin, a novel anticoagulant designed for patients with specific orphan diseases. This collaboration aims to explore strategic partnerships and licensing agreements, leveraging The Sage Group's expertise and resources. Tecarfarin has shown promise in clinical trials, addressing a significant unmet need in anticoagulation therapy.

Nov 30, 2023

Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023

Cadrenal Therapeutics, Inc. will present at the NobleCon 19 Conference on December 4, 2023. CEO Quang Pham will discuss tecarfarin, a late-stage anticoagulant aimed at preventing serious cardiovascular events in patients with rare conditions. A video of the presentation will be available online following the event.

Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update

Cadrenal Therapeutics announced its third-quarter corporate update, emphasizing its development of tecarfarin, a promising anticoagulant. With tecarfarin, the company aims to address unmet needs in patients with specific rare medical conditions where existing anticoagulants are unsuitable. The company is managing its finances prudently, having only spent $628,000 in the last quarter, and believes it has sufficient resources to initiate a pivotal trial in 2024. Despite potential for success, navigating regulatory pathways presents inherent risks.

Oct 9, 2023

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference

Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Fall 2023 Investor Conference on October 17, 2023. CEO Quang Pham will present in a webcast and a panel discussion focused on cardiovascular disorders. The company is developing tecarfarin, a novel anticoagulant aimed at preventing blood clots in patients with specific medical conditions.

Sep 5, 2023

Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress

Cadrenal Therapeutics emphasizes the need for a new Vitamin K Antagonist, tecarfarin, following insights from the European Society of Cardiology Congress. The FRAIL-AF trial indicated that switching from VKAs to DOACs in frail older patients may lead to increased bleeding without reducing thromboembolic events. Tecarfarin aims to address the limitations of current VKAs and has identified a significant market opportunity.

Aug 30, 2023

Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)

Cadrenal Therapeutics has announced an expanded evaluation of tecarfarin for patients with antiphospholipid syndrome (APS), a condition that increases the risk of blood clots. Tecarfarin is designed to overcome the limitations of warfarin, the current standard treatment. The company believes tecarfarin could significantly improve patient outcomes and has identified a substantial market opportunity for this treatment.

Aug 28, 2023

Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Cadrenal Therapeutics will participate in the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. The company's management team will hold meetings and present virtually, showcasing their late-stage anticoagulant, tecarfarin. This drug aims to prevent serious cardiovascular events in patients with specific medical conditions and has shown positive results in clinical trials.

Aug 18, 2023

CREATE A COVER SLIDE Cadrenal Therapeutics, Inc. NASDAQ: CVKD August 2023 2 Cautionary Statement Concerning Forward Looking Statements This document contains forward - looking statements. In addition, from time to time,

Cadrenal Therapeutics is focused on developing tecarfarin, a novel oral anticoagulant aimed at addressing anticoagulation challenges in patients with specific rare medical conditions. Tecarfarin aims to offer a more reliable option than existing treatments like warfarin and has received both Orphan Drug and Fast Track designations from the FDA. The company has invested approximately $90 million in the clinical development of tecarfarin, which is currently in Phase III trials for End Stage Kidney Disease with Atrial Fibrillation. With a potential market value exceeding $2 billion, tecarfarin is positioned to fill critical gaps in anticoagulation therapy.

Aug 10, 2023

Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update

Cadrenal Therapeutics recently provided a corporate update alongside its quarterly report for Q2 2023. The company highlighted the expanded potential of its anticoagulant tecarfarin beyond its initial indications. With estimated market opportunities amounting to $2.6 billion annually in the U.S. for treating patients with end-stage kidney disease, atrial fibrillation, and other indications, Cadrenal is positioning itself strategically within the anticoagulant market. The company's recent private financing has also improved its balance sheet, enhancing prospects for continued development and regulatory approval of tecarfarin.

Aug 1, 2023

Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases

Cadrenal Therapeutics is shifting its focus for tecarfarin, a novel anticoagulant, to patients with implanted medical devices for heart diseases, particularly those with left ventricular assist devices (LVADs). This decision is based on clinical data and market research indicating a significant need for effective anticoagulant treatment in this population. The company estimates an addressable market of approximately $600 million annually for this indication.

Jul 24, 2023

▼ -11.7%on this news· ran to -26% by day 3

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

Cadrenal Therapeutics has appointed Robert Lisicki to its Board of Directors, enhancing its leadership with his extensive experience in the biopharma industry. Lisicki, known for his role at Arena Pharmaceuticals, has been influential in significant M&A activities, which may bolster Cadrenal's growth strategy. He will focus on advancing tecarfarin, a potential breakthrough anticoagulant designed for patients with end-stage kidney disease and atrial fibrillation. This newly created board seat underscores Cadrenal's commitment to developing innovative treatments in targeted medical conditions.

Cadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Cadrenal Therapeutics has successfully closed a $7.5 million private placement, selling 4.28 million shares at $1.75 each. The funds will be used for working capital as the company continues to develop tecarfarin, an innovative anticoagulant. The offering included warrants for additional shares and was facilitated by H.C. Wainwright & Co.

Jul 12, 2023

▲ +29.3%on this newsshared move

Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Cadrenal Therapeutics announced a $7.5 million private placement intended for the issuance of shares priced at $1.75 each. The financing involves a sale of 4,285,715 shares and accompanying warrants and is expected to close on July 14, 2023. This funding is directed towards working capital as the company advances its late-stage oral anticoagulant, tecarfarin, which has shown potential in mitigating blood clot risks for patients with specific conditions. The private placement underscores investor interest in Cadrenal's development efforts.

May 10, 2023

Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update

Cadrenal Therapeutics provided a corporate update regarding their progress in the first quarter of 2023, particularly highlighting the receipt of Fast Track designation for their drug tecarfarin. This drug targets patients with end-stage renal disease and atrial fibrillation and has shown promise across multiple trials. The company plans to conduct a Phase 3 trial called ACTOR-AF to pave the way for a New Drug Application submission. If approved, the drug could reach a market potential of up to $1 billion annually.

Mar 27, 2023

CREATE A COVER SLIDE Cadrenal Therapeutics, Inc. NASDAQ: CVKD March 2023 2 Cautionary Statement Concerning Forward Looking Statements This document contains forward - looking statements. In addition, from time to time, w

Cadrenal Therapeutics is advancing tecarfarin through its pivotal Phase 3 clinical study aimed at preventing systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. This drug has been designated as an orphan drug and received Fast Track status, indicating its potential importance in a market where current treatment options are inadequate. The firm has invested heavily in this development, with a projected market potential of $1 billion, although many risks remain associated with the implementation and success of the clinical trials.

Jan 20, 2023